BriaCell Therapeutics Statistics Share Statistics BriaCell Therapeutics has 17.55M
shares outstanding. The number of shares has increased by 229.33%
in one year.
Shares Outstanding 17.55M Shares Change (YoY) 229.33% Shares Change (QoQ) 82.67% Owned by Institutions (%) 0% Shares Floating 17.07M Failed to Deliver (FTD) Shares 262,371 FTD / Avg. Volume 20.88%
Short Selling Information The latest short interest is 1.79M, so 10.22% of the outstanding
shares have been sold short.
Short Interest 1.79M Short % of Shares Out 10.22% Short % of Float 10.3% Short Ratio (days to cover) 1
Valuation Ratios PE Ratio 0 Forward PE -0.35 PS Ratio 0 Forward PS n/a PB Ratio -0.01 P/FCF Ratio 0 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for BriaCell Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.49,
with a Debt / Equity ratio of 0.
Current Ratio 0.49 Quick Ratio 0.49 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-294.78K Employee Count 16 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -92.43% in the
last 52 weeks. The beta is 1.41, so BriaCell Therapeutics's
price volatility has been higher than the market average.
Beta 1.41 52-Week Price Change -92.43% 50-Day Moving Average 2.17 200-Day Moving Average 5.6 Relative Strength Index (RSI) 21.83 Average Volume (20 Days) 1,256,627
Income Statement
Revenue n/a Gross Profit -82.58K Operating Income -32.81M Net Income -4.72M EBITDA -4.77M EBIT -4.85M Earnings Per Share (EPS) -6.03
Full Income Statement Balance Sheet The company has 862.09K in cash and 0 in
debt, giving a net cash position of 862.09K.
Cash & Cash Equivalents 862.09K Total Debt n/a Net Cash n/a Retained Earnings -85.48M Total Assets 17M Working Capital 10.45M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -24.13M
and capital expenditures -456.8K, giving a free cash flow of -24.58M.
Operating Cash Flow -24.13M Capital Expenditures -456.8K Free Cash Flow -24.58M FCF Per Share -22429.68
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields BCTX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for BCTX is $32,
which is 4537.7% higher than the current price. The consensus rating is "Buy".
Price Target $32 Price Target Difference 4537.7% Analyst Consensus Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jan 29, 2025. It was a
backward
split with a ratio of 1:15.
Last Split Date Jan 29, 2025 Split Type backward Split Ratio 1:15
Scores Altman Z-Score -11.02 Piotroski F-Score 1
